Action
Glutamate antagonist (NMDA receptor glycine site blocker); 5-nitro-6, 7-dichloro-2,3-quinoxalinedione

Status
Clinical development halted at Phase I 4/97. "April 29, 1997 CoCensys and Novartis Pharma announced that Novartis has decided not to participate further in the development of ACEA 1021, CoCensys’ compound for the treatment of stroke and traumatic brain injury. The decision was influenced by preliminary results from a recently completed Phase I safety trail that showed crystals of ACEA 1021 in the urine of some of the subjects. . . . ACEA 1021 has been studied in a series of Phase I clinical trials involving 142 healthy volunteers and stroke patients. There has been no evidence in any of the trials of the dose-limiting CNS side effects, such as hallucinations, delirium, agitation or cardiovascular effects, that have been reported with some other experimental drugs for stroke and head trauma."

Trial(s)
  = Ongoing
  = Completed

UID: 2